Quick Answer
Quince Therapeutics, Inc. reported Net Income of -$56.83 million for fiscal year 2024.
Quince Therapeutics, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Net Income | -$56.83M -81.1% |
-$31.39M +39.2% |
-$51.66M +42.6% |
-$89.94M -17.0% |
-$76.85M -107.8% |
-$36.98M -196.4% |
| Diluted EPS | -$1.31 -56.0% |
-$0.84 +45.5% |
-$1.54 +49.2% |
-$3.03 | — | — |
| Total Assets | $114.48M -31.8% |
$167.90M +61.6% |
$103.91M -22.0% |
$133.23M -29.7% |
$189.47M +52.3% |
$124.37M +70.7% |
| Cash and Equivalents | — | — | — | — | — | $51.21M +105.9% |
| Long-Term Debt | $14.32M +6.6% |
$13.43M | $0.00 | — | — | — |
| Stockholders Equity | $30.15M -64.6% |
$85.08M -15.4% |
$100.59M -15.2% |
$118.59M -31.2% |
$172.26M +49.2% |
$115.48M +453.9% |
| R&D Expense | $18.59M +96.8% |
$9.45M -62.5% |
$25.18M -58.6% |
$60.80M -0.8% |
$61.31M +102.9% |
$30.21M +199.6% |
| Operating Income | -$57.28M -65.5% |
-$34.62M +33.4% |
-$52.02M +42.4% |
-$90.32M -14.5% |
-$78.89M -101.4% |
-$39.17M -223.2% |
| Shares Outstanding | 44.00M +2.4% |
42.97M +18.9% |
36.14M +20.2% |
30.07M +1.8% |
29.54M +10.0% |
26.87M +687.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$13.44M | -144.8% | +16.2% |
| Diluted EPS | September 30, 2025 | -$0.25 | -92.3% | +26.5% |
| Total Assets | September 30, 2025 | $109.90M | -13.1% | -6.2% |
| Cash and Equivalents | September 30, 2025 | $6.45M | — | -61.7% |
| Long-Term Debt | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | September 30, 2025 | $1.06M | -97.6% | -91.0% |
| R&D Expense | September 30, 2025 | $8.08M | +64.4% | +23.3% |
| Operating Income | September 30, 2025 | -$13.43M | -129.1% | -28.8% |
| Shares Outstanding | September 30, 2025 | 54.49M | +25.9% | +1.6% |
- Quince Therapeutics, Inc. reported Net Income of -$56.83 million for fiscal year 2024.
- Quince Therapeutics, Inc. showed a decrease of -81.1% in Net Income compared to the prior fiscal year.
- Quince Therapeutics, Inc. reported Diluted EPS of $1.31 per share (loss) for fiscal year 2024.
- Quince Therapeutics, Inc. showed a decrease of -56.0% in Diluted EPS compared to the prior fiscal year.
- Quince Therapeutics, Inc. reported Total Assets of $114.48 million for fiscal year 2024.
- Quince Therapeutics, Inc. showed a decrease of -31.8% in Total Assets compared to the prior fiscal year.
- Quince Therapeutics, Inc. reported Cash and Equivalents of $51.21 million for fiscal year 2019.
- Quince Therapeutics, Inc. showed an increase of +105.9% in Cash and Equivalents compared to the prior fiscal year.
- Quince Therapeutics, Inc. reported Long-Term Debt of $14.32 million for fiscal year 2024.
- Quince Therapeutics, Inc. showed an increase of +6.6% in Long-Term Debt compared to the prior fiscal year.
- Quince Therapeutics, Inc. reported Stockholders Equity of $30.15 million for fiscal year 2024.
- Quince Therapeutics, Inc. showed a decrease of -64.6% in Stockholders Equity compared to the prior fiscal year.
- Quince Therapeutics, Inc. reported R&D Expense of $18.59 million for fiscal year 2024.
- Quince Therapeutics, Inc. showed an increase of +96.8% in R&D Expense compared to the prior fiscal year.
- Quince Therapeutics, Inc. reported Operating Income of -$57.28 million for fiscal year 2024.
- Quince Therapeutics, Inc. showed a decrease of -65.5% in Operating Income compared to the prior fiscal year.
- Quince Therapeutics, Inc. reported Shares Outstanding of 44.00 million shares for fiscal year 2024.
- Quince Therapeutics, Inc. showed an increase of +2.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: